Jason Buxbaum, MHSA, project manager, V-BID Health; and Robert Dubois, MD, PhD, chief scientific officer, National Pharmaceutical Council, discuss low-value services, their financial impact, what states are doing to address them, and challenges with addressing them.
As conversations surrounding rising healthcare costs persist, the idea of addressing low-value services has caught the attention of health professionals nationwide. Value-Based Insurance Design (V-BID) Health’s Task Force on Low-Value Care has identified a top 5 list of low-value clinical services that can be targeted.
We spoke with Jason Buxbaum, MHSA, project manager, V-BID Health, about which 5 low-value services topped the list, the financial impact they have, and how states are attempting to address them.
Once low-value services are identified, healthcare professionals face another challenge: turning conversation into something actionable. We discussed the challenges with addressing these low-value services with Buxbaum and Robert Dubois, MD, PhD, chief scientific officer, National Pharmaceutical Council.
Listen above or through one of these podcast services:
iTunes: http://apple.co/2eYWTss
TuneIn: http://bit.ly/2gv7iwj
Stitcher: http://bit.ly/2gCqtFg
The Myth of Average: Why Individual Patient Differences Matter
January 19th 2022In the newly-updated booklet, The Myth of Average: Why Individual Patient Differences Matter, the National Pharmaceutical Council (NPC) explores the barriers patients face when navigating the health care system and identifies opportunities for health care decision-makers to build better health care benefits and improve patient access to needed treatments.
Read More
National Pharmaceutical Council Appoints Dr. Sharon Phares as Chief Scientific Officer
January 18th 2022The National Pharmaceutical Council (NPC), a health policy research organization dedicated to the advancement of good evidence, science and medical innovation, announced the appointment of Sharon Phares, PhD, MPH, as chief scientific officer.
Read More